Trial Profile
The Xolair Pregnancy Registry: An Observational Study of the Use and Safety of Xolair (Omalizumab) During Pregnancy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Apr 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Acronyms EXPECT
- Sponsors Genentech
- 01 Mar 2021 Results (N=30) of post hoc analysis assessing the perinatal outcomes of patients enrolled in EXPECT who received Omalizumab for CSU during their pregnancy presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 27 May 2019 Results published in the Journal of Allergy and Clinical Immunology
- 25 Feb 2019 Results presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology